Laboratorios Rubió ended 2021 with some good news: we achieved our objective to enter the OTC segment in Spain with the acquisition of the Fisiopharma company. This operation has put us on the road to diversification beyond prescription medicines.
Fisiopharma was founded five years ago by Javier Sánchez and Alberto Berti, and specialises in nutraceuticals, as well as products aimed at neuropathies of the central nervous system, and muscle and joint tissue.
Laboratorio Rubió’s acquisition of Fisiopharma forms part of the strategic plan being implementing as a driver of growth, based on innovation and the entry into new business segments, in this case the nutraceuticals market.
Thus, with this operation we have strengthened the line of food supplements and our goal for this year is to achieve a turnover of €92 million.
We are convinced that the new Fisiopharma products, which complement most of our medicines as they act on the same therapeutic areas, will enable us to create synergies in both the prevention and treatment of diseases, to consequently respond to patients’ needs.
For Laboratorios Rubió full collaboration with the doctor and pharmacy is indispensable, given that we continue to rely on professional advice when it comes to distributing our products. This way we ensure that patients receive the products that are really the most appropriate for their health issues, they are compatible with their medication and, furthermore, we can be certain that they are used properly.
